Detalles de la búsqueda
1.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657462
2.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357420
3.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Lancet Oncol
; 18(6): 743-754, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526538
4.
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Breast Cancer Res Treat
; 157(1): 101-8, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27116182
5.
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Lancet Oncol
; 15(4): 474-82, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24636210
6.
Challenges to effective cancer control in China, India, and Russia.
Lancet Oncol
; 15(5): 489-538, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24731404
7.
Planning cancer control in Latin America and the Caribbean.
Lancet Oncol
; 14(5): 391-436, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23628188
8.
[Ultrasound guided breast biopsy--a retrospective study and literature review]. / Biopsija dojke pod kontrolom ultrazvuka--retrospektivna studija i pregled literature.
Lijec Vjesn
; 134(9-10): 270-5, 2012.
Artículo
en Croata
| MEDLINE | ID: mdl-23297511
9.
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Cancer Chemother Pharmacol
; 88(3): 499-512, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34106303
10.
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
J Clin Pharmacol
; 61(8): 1096-1105, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33719071
11.
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
J Clin Pharmacol
; 59(5): 702-716, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570763
12.
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
J Natl Cancer Inst
; 110(9): 1003-1008, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29554282
13.
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.
Cancer Discov
; 8(3): 336-353, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29242214
14.
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Cancer Chemother Pharmacol
; 89(4): 571-572, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34559287
15.
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
J Clin Oncol
; 35(26): 3030-3038, 2017 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28437161
16.
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Breast
; 22 Suppl 2: S171-5, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24074782
17.
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer.
Med Oncol
; 29(3): 1586-91, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22116775
18.
Significance of epidermal growth factor receptor expression in breast cancer.
Med Oncol
; 28 Suppl 1: S121-8, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21104342
Resultados
1 -
18
de 18
1
Próxima >
>>